Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 246

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 246
---
 is 6,923,990, based on a conversion price
of $0.63 and assuming an interest rate of 14.75% through the fifty-four (54) month maturity of the Notes. Further the conversion price
of the Note is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar
transactions, and full-ratchet adjustment in connection with a subsequent offering at a per share price less than the fixed conversion
price then in effect. The holder of the Note may convert any portion of the outstanding portion of the Note into validly issued, fully
paid and non-assessable Class A Shares at the conversion price. No fractional Class A Shares are issuable upon any such conversion. If
the issuance would result in the issuance of a fraction of a Class A Share, the Company shall round such fraction of a Class A Share up
to the nearest whole share. The Fourth Tranche Note is included as Exhibit 4.1 in the Form 6-K filed on July 16, 2025, which is incorporated herein by reference.

Between November 7, 2024 and
the date of this prospectus, the Company received gross proceeds of $7,850,000 and issued an aggregate of 573,837 Class A Ordinary Shares
(on a post Reverse Stock Splits basis) to the Buyers.

The Company may receive up
to approximately $18,540,961 in additional net proceeds from the 2024 Debt Financing if all remaining Additional Notes in the aggregate
principal amount of $3,150,000 (together with the Fourth Tranche Note and Fifth Tranche Note,
the “Remaining Additional Notes”) issuable pursuant to the Securities Purchase Agreement are sold and (ii) the Series A Warrants
are increased by 10,157,580 assuming that (A) all Remaining Additional Notes are sold and (B) an Additional Share Price is equal to $1.3513
and (iii) all of the Warrants are exercised in full, based on the following assumptions (x) approximately $23,909,021 in net proceeds
are received from the exercise of the Series A Warrants, assuming that the Series A Warrants are exercised in full at an exercise price
of $1.8258 and the number of Ordinary Shares issuable upon exercise of the Series A Warrants equals 13,095,093, (y) approximately $1,485
in net proceeds are received from the exercise of the